telmisartan has been researched along with Cholangiocellular Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiyo, T; Fujihara, S; Himoto, T; Iwama, H; Kobara, H; Kobayashi, K; Masaki, T; Mori, H; Morishita, A; Nakahara, M; Okano, K; Oura, K; Samukawa, E; Suzuki, Y; Tadokoro, T; Yamana, Y | 1 |
| Fujimura, T; Fushida, S; Hayashi, H; Kayahara, M; Kitagawa, H; Nakagawara, H; Nakanuma, S; Ohnishi, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Tani, T | 1 |
2 other study(ies) available for telmisartan and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Bile Duct Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Random Allocation; Resting Phase, Cell Cycle; Telmisartan; Xenograft Model Antitumor Assays | 2017 |
[The role of renin-angiotensin system independent angiotensin II production in progression and fibrosis of intrahepatic cholangiocarcinoma].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Disease Progression; Fibrosis; Hepatic Stellate Cells; Humans; Receptor, Angiotensin, Type 1; Telmisartan | 2010 |